Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment
Saturday, February 21, 2026, 6:22 am / permalink 19517 / 2 stories in 18 days
Judge orders Leapfrog to remove safety grades for five Florida hospitals (22 hrs)
Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (41 hrs)
White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.